3S Bio raises a healthy $711m via HK IPO

The mainland Chinese biotech firm generated strong demand, with the retail tranche of the offering on the Hong Kong bourse 200-times oversubscribed.

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES